FINWIRES · TerminalLIVE
FINWIRES

$IEX

23 stories mentioning IEXUpdated 7d ago

Every FINWIRES story that references IEX, newest first.

What are analysts saying about IEX?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on IEX?

Wire

IDEX Executives Highlight Value of 80/20 Operating Model, Growth Strategy, Oppenheimer Says

IDEX (IEX) leadership emphasized the value of its 80/20 operating model, integrated growth strategy, and multi-year pivot toward advantaged markets, Oppenheimer said in a note emailed Wednesday, following investor meetings with company executives.The brokerage remains bullish on Health & Science Technologies-led outgrowth expected over the near-to-medium term and a mix-accretive top-line rebound in Fluid & Metering Technologies and Fire & Safety/Diversified Products segments, according to the note.IDEX's growth strategy and its success is most prominent in HST positioning and runway, the note added. For FMT segment, Oppenheimer sees a growth inflection, given favorable short-cycle trends and strong Water platform growth. In FSDP, the company should benefit from ongoing BAND-IT strength and the North American firetruck refresh cycle, the brokerage added.Oppenheimer expects share repurchases of approximately $75 million each quarter over the near-term, with potential re-acceleration of tuck-in/bolt-on acquisitions during 2027.The brokerage raised its 2026 and 2027 EPS estimates to $8.85 and $9.95 from $8.82 and $9.85, respectively.Oppenheimer kept an outperform rating on IDEX and raised its price target to $270 per share from $265.Price: $226.02, Change: $+0.36, Percent Change: +0.16%

$IEX
Nordson Raises Fiscal 2026 Outlook on Strong Demand Following Third-Quarter Beat
US Markets

Nordson Raises Fiscal 2026 Outlook on Strong Demand Following Third-Quarter Beat

Nordson (NDSN) shares advanced early Thursday after the precision technology company lifted its full-year outlook amid rising demand in key end markets, while the firm reported better-than-expected fiscal third-quarter results.Adjusted earnings are now anticipated to come in between $11.80 and $12 per share for fiscal 2026, the company said late Wednesday, up from its previous projections of $11.30 to $11.80. Revenue is pegged at $3.04 billion to $3.08 billion, compared with the prior guidance of $2.93 billion to $3.01 billion.The current consensus on FactSet is for non-GAAP EPS of $11.64 and sales of $2.99 billion for the fiscal year. The company's stock jumped 7% in the most recent premarket activity.Nordson said it has entered the current three-month period with strong demand momentum and backlog up 35% year over year."Based on backlog and order entry momentum, we expect the strong sales of the first nine months to continue through the fourth quarter," Chief Executive Sundaram Nagarajan said in a statement. "We are delivering above-market organic growth through accelerating demand in key end markets."For the quarter ended July, the firm's adjusted EPS climbed to $3.25 from $2.73 last year, topping the Street's view for $3.09. Sales improved 10% to $817.7 million, ahead of the average analyst estimate on FactSet of $779.5 million."The strong momentum of the first half continued through the third quarter, delivering results above the high-end of our most recent earnings guidance," according to Nagarajan.Revenue in the industrial precision solutions segment increased 4.7% to $367.2 million, including a 3% gain in organic sales amid strength in the packaging, industrial coatings, polymer processing and nonwovens product lines, the company said. The medical and fluid solutions business saw sales increase 5% to $230.5 million, while advanced technology solutions jumped 28% to $219.9 million.Revenue rose across all geographies the firm operates in, led by growth of 22% in the Asia-Pacific region.Last month, rivals Dover (DOV) and Graco (GGG) each reported second-quarter adjusted earnings above market estimates, while both companies' revenue fell short of expectations. Industrial equipment maker IDEX (IEX) recorded better-than-expected second-quarter results.

$DOV$GGG$IEX$NDSN
Research

Mizuho Upgrades IDEX to Outperform From Neutral, Adjusts Price Target to $280 From $210

IDEX (IEX) has an average rating of overweight and mean price target of $256.69, according to analysts polled by FactSet.

$IEX
Wire

DA Davidson Adjusts Price Target on IDEX to $240 From $230

IDEX (IEX) has an average rating of overweight and mean price target of $250.92, according to analysts polled by FactSet.Price: $233.99, Change: $-2.99, Percent Change: -1.26%

$IEX
Wire

Argus Adjusts Price Target on IDEX to $260 From $250

IDEX (IEX) has an average rating of overweight and mean price target of $250.92, according to analysts polled by FactSet.Price: $233.98, Change: $-3.00, Percent Change: -1.27%

$IEX
Wire

BMO Capital Adjusts Price Target on IDEX to $251 From $230, Maintains Market Perform Rating

IDEX (IEX) has an average rating of overweight and mean price target of $250.15, according to analysts polled by FactSet.Price: $235.18, Change: $+5.66, Percent Change: +2.47%

$IEX
Wire

Baird Adjusts Price Target on IDEX to $274 From $257, Maintains Outperform Rating

IDEX (IEX) has an average rating of overweight and mean price target of $250.15, according to analysts polled by FactSet.Price: $235.18, Change: $+5.66, Percent Change: +2.47%

$IEX
Wire

BNP Paribas Adjusts Price Target on IDEX to $215 From $210, Maintains Neutral Rating

IDEX (IEX) has an average rating of overweight and mean price target of $250.15, according to analysts polled by FactSet.Price: $235.18, Change: $+5.66, Percent Change: +2.47%

$IEX
Wire

IDEX Keeps Quarterly Dividend at $0.73 a Share, Payable July 24 to Shareholders of Record on July 6

IDEX Keeps Quarterly Dividend at $0.73 a Share, Payable July 24 to Shareholders of Record on July 6

$IEX
Insider Trading

Idex Insider Sold Shares Worth $3,311,195, According to a Recent SEC Filing

Eric D Ashleman, Director, CEO, and President, on May 11, 2026, sold 15,385 shares in Idex (IEX) for $3,311,195. Following the Form 4 filing with the SEC, Ashleman has control over a total of 66,658 common shares of the company, with 66,658 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/832101/000090514826002252/xslF345X05/form4.xml

$IEX
Wire

IDEX Raises Quarterly Dividend to $0.73 a Share From $0.71, Payable June 5 to Shareholders of Record on May 22

IDEX Raises Quarterly Dividend to $0.73 a Share From $0.71, Payable June 5 to Shareholders of Record on May 22

$IEX
Wire

Argus Adjusts Price Target on IDEX to $250 From $240

IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.Price: $214.86, Change: $-2.99, Percent Change: -1.37%

$IEX
Research

Research Alert: CFRA Reiterates Hold Opinion On Shares Of Iex

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $235 from $220 following Q1, valuing shares at 26x our 2027 EPS outlook of $9.04 (up from $8.99; 2026 EPS view revised to $8.50 from $8.28). IEX posted a robust Q1, with operating EPS of $2.00 rising 14% Y/Y and exceeding consensus by $0.23, propelled by standout performance in Health & Science Tech. Organic sales growth accelerated to 5% Y/Y from 1% in Q4, while orders hit a record $988M (up 10% Y/Y), signaling broadened demand. Health & Science Tech was the clear growth engine, delivering 11% organic sales growth alongside 100-bp adjusted EBITDA margin expansion to 26.6%. This strength was fueled by AI-driven demand for data center power solutions, semiconductor applications, and space & defense markets. Despite gross margin compression of 40 bps, adjusted EBITDA margin expanded 50 bps to 26%, suggesting the company's 80/20 initiatives are gaining traction.Overall, Q1 results were encouraging and contributed to our raised growth outlook for the year.

$IEX
Research

Research Alert: CFRA Reiterates Hold Opinion On Shares Of Iex

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $235 from $220 following Q1, valuing shares at 26x our 2027 EPS outlook of $9.04 (up from $8.99; 2026 EPS view revised to $8.50 from $8.28). IEX posted a robust Q1, with operating EPS of $2.00 rising 14% Y/Y and exceeding consensus by $0.23, propelled by standout performance in Health & Science Tech. Organic sales growth accelerated to 5% Y/Y from 1% in Q4, while orders hit a record $988M (up 10% Y/Y), signaling broadened demand. Health & Science Tech was the clear growth engine, delivering 11% organic sales growth alongside 100-bp adjusted EBITDA margin expansion to 26.6%. This strength was fueled by AI-driven demand for data center power solutions, semiconductor applications, and space & defense markets. Despite gross margin compression of 40 bps, adjusted EBITDA margin expanded 50 bps to 26%, suggesting the company's 80/20 initiatives are gaining traction.Overall, Q1 results were encouraging and contributed to our raised growth outlook for the year.

$IEX
Wire

Citigroup Adjusts Price Target on IDEX to $252 From $243

IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.Price: $218.37, Change: $+1.03, Percent Change: +0.47%

$IEX
Wire

Stifel Adjusts Price Target on IDEX to $250 From $241

IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.Price: $218.37, Change: $+1.03, Percent Change: +0.47%

$IEX
Wire

BMO Capital Adjusts Price Target on IDEX to $230 From $214

IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.Price: $218.48, Change: $+1.14, Percent Change: +0.52%

$IEX
Wire

Baird Adjusts Price Target on IDEX to $257 From $247

IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.Price: $218.35, Change: $+1.01, Percent Change: +0.46%

$IEX
Wire

Mizuho Adjusts Price Target on IDEX to $210 From $170

IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.Price: $218.35, Change: $+1.01, Percent Change: +0.46%

$IEX
Wire

BNP Paribas Adjusts Price Target on IDEX to $210 From $200

IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.Price: $218.35, Change: $+1.01, Percent Change: +0.46%

$IEX

Showing 1-20 of 23

Track with the FINWIRES app suite

FolioX
FolioX
Track IEX in your portfolio
WheelAI
WheelAI
Analyze IEX options with the wheel strategy
StockInsider
StockInsider
See market sentiment on IEX